All 1 tracked stories fall under one category: health-it. TaiGen Biotechnology is most often covered alongside ISM4808, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 3 original sources each against 3.6 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about TaiGen Biotechnology
All 1 tracked stories fall under one category: health-it. TaiGen Biotechnology is most often covered alongside ISM4808, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 3 original sources each against 3.6 for the same window. At 6, the average consequence score sits above the same-window beat average of 5.8. We currently track 1 Healthcare story that mention TaiGen Biotechnology, all published on March 6, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering TaiGen Biotechnology. Shared-story counts are live from our verified record — not editorial picks.
Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.